Redeye is encouraged by Isofol starting analysis of AGENT data, with top-line data some two to four ...
The Thoracic recovery continues, and together with well-balanced and high organic growth, we expect ...
We have lowered our 2022e sales by 9% following a weaker short-term outlook for wind power.
Scanfil’s profitability is set to improve over the course of the year despite the still tight compon...
Under första kvartalet var Svedbergs organiska tillväxt goda 13 procent.
Taaleri is selling its stake in Ficolo and exiting Taaleri Datacenter, through which Taaleri and its...
Nitro Games delivered a solid report. Revenue was 24% ahead of our expectations, while profitability...
Redeye notes that PiezoMotor continues to show impressive growth in the first quarter, proforma 24% ...
Ahead of Rovio's Q1 report, we adjust our estimates mainly for FX tailwinds from the stronger USD.
CapMan will report its Q1 results on 28 April. We take a more cautious view on fair value changes an...
BankNordik has now fully distributed excess capital from the sale of its Danish business – one year ...
Redeye’s expectations on the Q1 numbers were rather modest as Heliospectra is in a transitional phas...
Cline Scientific (”Cline” eller ”Bolaget”) har genom egenutvecklad och patenterad teknologi just nu ...
Q1-rapporten Hansa släppte igår sin rapport för det första kvartalet 2022.
Stark tillväxt Bolagets verksamhetsuppdatering för Q1 2022 (full rapportering sker på halvårsbasis) ...
Stark resultatutveckling i Q1'22 BE Group levererade ett underliggande rörelseresultat på 180 mkr i ...
Vitrolife’s previous Q1 confirms more normal activity with improved organic growth to 11% from the l...
The first quarter was slow in terms of sales as no system sales were recorded.
Redeye comments on Active Biotech’s first quarter report and updates its valuation and forecast.
Plejd fortsätter växa i hög takt med ständigt förbättrad lönsamhet.
